Syneos Health Target Price Raised Amid $7.1B Acquisition News: Analyst Provides Insight

Loading...
Loading...
  • Mizuho analyst Ann Hynes reiterated a Neutral rating on the shares of Syneos Health, Inc. SYNHraising the price target to $43 from $38.
  • The company recently announced a definitive agreement to be purchased by a group of private equity firms led by Elliott Investment Management for $7.1 billion, including the assumption of all debt. The price target has been raised, focusing on the pending acquisition deal. 
  • Also Read: Syneos To Be Acquired By Private Investment Consortium For $7.1B, Q1 Earnings Beat Expectations
  • Completion of the transaction is expected in the second half of 2023.
  • Hynes thinks this deal represents a purchase multiple of ~10.1x 2023 adjusted EBITDA, below historical CRO (Contract Research Organization) deals.
  • The purchase multiple is below the CRO industry's ten, five and two-year historical EV/EBITDA trading averages of 13.4x, 15.5x and 16.5x, respectively.
  • The analyst reiterated FY23 adjusted EPS estimate at $3.30.
  • However, considering challenged operational results in the just-reported first quarter of FY23, the analyst lowered 2024 estimates by $0.50 to $3.75.
  • Price Action: SYNH is trading lower by 0.38% to $41.56 in the market session on the last check Tuesday.
Posted In: Analyst ColorNewsHealth CarePrice TargetReiterationAnalyst RatingsGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...